C91.A Mature B-cell leukemia Burkitt-type

Name of the Condition

• Mature B-cell leukemia Burkitt-type
• ICD-10 Code: C91.A

Summary

Mature B-cell leukemia Burkitt-type is a rare, aggressive form of leukemia that originates from mature B lymphocytes. It is characterized by rapid proliferation of abnormal B cells, often involving the bone marrow, blood, and other tissues. This condition is part of the Burkitt lymphoma/leukemia spectrum and is distinguished by its high growth rate and specific genetic abnormalities.

Causes

The exact cause of mature B-cell leukemia Burkitt-type is not fully understood, but it involves genetic mutations, such as translocations involving the MYC gene, that drive uncontrolled B-cell proliferation. Contributing factors may include viral infections (e.g., Epstein-Barr virus) and immunodeficiency, though these are not universally present.

Risk Factors

• Immunodeficiency (e.g., HIV/AIDS)
• Epstein-Barr virus infection
• Certain genetic predispositions
• Geographic or demographic associations (e.g., higher incidence in some regions)

Symptoms

• Rapid onset of symptoms
• Fatigue and weakness
• Fever
• Unexplained weight loss
• Abdominal pain or swelling (due to organ involvement)
• Enlarged lymph nodes
• Neurological symptoms (if central nervous system is affected)

Diagnosis

Diagnosis involves a physical examination, blood tests to assess cell counts and identify abnormal B cells, and bone marrow biopsy to confirm the presence of Burkitt-type leukemia. Additional tests, such as flow cytometry or genetic analysis, may be used to identify specific markers and translocations.

Treatment Options

Treatment typically involves intensive chemotherapy regimens, often including agents like cyclophosphamide, vincristine, and high-dose methotrexate. Stem cell transplantation may be considered for high-risk or relapsed cases. Supportive care, such as managing infections or side effects, is also critical.

Prognosis and Follow-Up

Prognosis depends on factors like age, overall health, and response to treatment. With aggressive therapy, remission rates can be high, but relapse is possible. Follow-up includes regular monitoring of blood counts, imaging, and clinical assessments to detect recurrence or complications.

Complications

• Tumor lysis syndrome (due to rapid cell breakdown)
• Infections (from impaired immune function)
• Organ dysfunction (e.g., kidney or liver involvement)
• Neurological issues (if the central nervous system is affected)

Lifestyle & Prevention

No specific preventive measures are known, but maintaining a healthy immune system and avoiding known risk factors (e.g., reducing exposure to viruses) may be beneficial. Supportive care, such as nutrition and rest, can help manage symptoms during treatment.

When to Seek Professional Help

Seek immediate medical attention for symptoms like severe fatigue, unexplained weight loss, fever, or abdominal pain, especially if they worsen rapidly. Early diagnosis and treatment are critical for managing this aggressive condition.

Tips for Medical Coders

Document the diagnosis with the specific code C91.A for mature B-cell leukemia Burkitt-type. Ensure clinical documentation supports the aggressive nature and B-cell origin of the leukemia, as this distinguishes it from other lymphoid leukemias. Include details about genetic markers or translocations if available, as they may impact coding specificity.